2022
Effectiveness of a COVID-19 Additional Primary or Booster Vaccine Dose in Preventing SARS-CoV-2 Infection Among Nursing Home Residents During Widespread Circulation of the Omicron Variant — United States, February 14–March 27, 2022
Prasad N, Derado G, Nanduri S, Reses H, Dubendris H, Wong E, Soe M, Li Q, Dollard P, Bagchi S, Edwards J, Shang N, Budnitz D, Bell J, Verani J, Benin A, Link-Gelles R, Jernigan J, Pilishvili T. Effectiveness of a COVID-19 Additional Primary or Booster Vaccine Dose in Preventing SARS-CoV-2 Infection Among Nursing Home Residents During Widespread Circulation of the Omicron Variant — United States, February 14–March 27, 2022. MMWR Morbidity And Mortality Weekly Report 2022, 71: 633-637. PMID: 35511708, PMCID: PMC9098239, DOI: 10.15585/mmwr.mm7118a4.Peer-Reviewed Original ResearchConceptsNational Healthcare Safety NetworkNursing home residentsPrimary series vaccinationSkilled nursing facilitiesBooster vaccine doseRelative vaccine effectivenessBooster doseVaccine effectivenessHome residentsSeries vaccinationVaccine doseCDC's National Healthcare Safety NetworkPreventing SARS-CoV-2 InfectionCOVID-19COVID-19-associated morbidityEarly COVID-19 vaccinationCOVID-19 vaccine doseSARS-CoV-2 infectionOmicron variant infectionVaccine-induced immunityNursing home staff membersPrimary doseVaccination coverage dataCOVID-19 prevention strategiesCOVID-19 vaccination
2021
Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant — National Healthcare Safety Network, March 1–August 1, 2021
Nanduri S, Pilishvili T, Derado G, Soe M, Dollard P, Wu H, Li Q, Bagchi S, Dubendris H, Link-Gelles R, Jernigan J, Budnitz D, Bell J, Benin A, Shang N, Edwards J, Verani J, Schrag S. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant — National Healthcare Safety Network, March 1–August 1, 2021. MMWR Morbidity And Mortality Weekly Report 2021, 70: 1163-1166. PMID: 34437519, PMCID: PMC8389386, DOI: 10.15585/mmwr.mm7034e3.Peer-Reviewed Original ResearchConceptsNational Healthcare Safety NetworkSARS-CoV-2 infectionNursing home residentsLong-term care facility residentsMRNA COVID-19 vaccineCOVID-19 vaccineVaccine effectivenessCare facility residentsHome residentsDelta variantPfizer-BioNTechModerna vaccineMRNA vaccinesFacility residentsNursing homesCDC's National Healthcare Safety NetworkPreventing SARS-CoV-2 InfectionSevere COVID-19-associated outcomesVaccine-induced immunityNursing home staff membersProtective immune responseCOVID-19 prevention strategiesWeekly reportsEmergency use authorizationSkilled nursing facilities
2003
Effectiveness of the 23-Valent Polysaccharide Vaccine against Invasive Pneumococcal Disease in Navajo Adults
Benin AL, O'Brien KL, Watt JP, Reid R, Zell ER, Katz S, Donaldson C, Parkinson A, Schuchat A, Santosham M, Whitney CG. Effectiveness of the 23-Valent Polysaccharide Vaccine against Invasive Pneumococcal Disease in Navajo Adults. The Journal Of Infectious Diseases 2003, 188: 81-89. PMID: 12825175, DOI: 10.1086/375782.Peer-Reviewed Original ResearchConceptsInvasive pneumococcal diseaseOverall vaccine effectivenessNavajo adultsPneumococcal diseaseCase patientsControl patientsPolysaccharide vaccineVaccine effectivenessGeneral United States populationSerious pneumococcal diseasePneumococcal polysaccharide vaccineCohort methodologyUnited States populationCase-control setsActive surveillanceObservational studyMedical conditionsPatientsMedical careDiseaseAdultsDiabetesRegression analysisVaccineAlcoholism